Form 4: Heron Therapeutics Executive Acquires Shares
Insider Transaction Report
Heron Therapeutics EVP and CFO, Ira Duarte, acquired shares through restricted stock units and an employee stock purchase plan.
Summary
- Ira Duarte, EVP and Chief Financial Officer of Heron Therapeutics, Inc., reported transactions on April 30, 2026.
- Duarte acquired 11,694 shares of common stock through the vesting of restricted stock units (RSUs).
- Additionally, 13,535 shares were acquired through RSUs.
- A total of 11,023 shares were acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2026.
- Following these transactions, Duarte beneficially owns 227,570 shares directly and an additional 252,128 shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions related to equity compensation rather than new strategic developments or financial performance.
Positives
- Executive leadership participation in equity ownership through RSUs and ESPP demonstrates alignment with shareholder interests.
- Acquisition of shares by the CFO can be interpreted as a positive signal of confidence in the company's future prospects.
Future Outlook
The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently provide strategic insights. The acquisition of shares by a CFO is a common occurrence and reflects the typical compensation and incentive structures within the biotechnology and pharmaceutical industry.
Stakeholder Impact
- Shareholders: The acquisition of shares by the CFO may be viewed positively as it indicates continued investment by management in the company.
- Employees: The use of an Employee Stock Purchase Plan suggests ongoing equity incentive programs for employees.
- Creditors: No direct impact is indicated.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | First installment of RSU vesting begins. |
| 01/30/2026 | Date of Grant for 216,562 RSUs. |
| 04/30/2026 | Transaction date for acquisition of shares via RSUs and Employee Stock Purchase Plan. |
| 05/04/2026 | Date of filing for the Form 4. |
Keywords
Form 4, SEC Filing, Heron Therapeutics, HRTX, Insider Trading, Stock Acquisition, Restricted Stock Units, Employee Stock Purchase Plan, Ira Duarte, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.